Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Jan 12, 2018 (9 years ago)

Levofloxacin in 5% Dextrose Injection

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Presence of Particulate Matter; contains visible particulate matter identified as mold.

Cause type: Microbial contamination

Bacteria, mold, yeast or other microorganisms detected in the product. Contamination can occur from water systems, equipment or handling, and can cause infection. All microbial contamination recalls.

What was recalled

Levofloxacin in 5% Dextrose Injection, 250 mg/50 mL (5 mg/mL), 50 mL Single-Use flexible container, Rx Only, Manufactured for: AuroMedics Pharma LLC 6 Wheeling Drive, Dayton, NJ 08810 Manufactured for: Aurobindo Pharma Limited IDA, Pashamylaram - 502307, India ---- NDC 55150-243-46

Affected NDC 55150-0243-46

Compare with the code on your package — it is the most precise check available.

Drug: Levofloxacin

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Levofloxacin
Levofloxacin in 5% Dextrose
NDC 55150-0243
LEVOFLOXACIN 250 mg/50mL Injection, Solution
Intravenous
Eugia US LLC Rx
Recalling firm
AuroMedics Pharma LLC
NDC code
55150-243-46
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0574-2018 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Levofloxacin recalls

See all
Class III · Low risk

Levofloxacin Tablets

Mismatching of the embossing on the tablets (T7) with the embossing mentioned in the package insert (ML63) in the distributed bottles.

Terminated Labeling / mix-up Macleods Pharma USA, INC NDC 33342-022-08 D-0162-2023

Other recalls by AuroMedics Pharma LLC

All 2018 recalls
Class II · Moderate risk

Acyclovir Sodium Injection

Presence of Particulate Matter: Customer complaint for a dark red, brown and black particulate floating inside vial.

Completed Particulate / foreign matter AuroMedics Pharma LLC NDC 55150-154-10 D-0013-2023